Paclitaxel in the belly plus chemo vs chemo alone for stomach cancer spread
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests whether adding chemotherapy directly into the abdomen (intraperitoneal paclitaxel) to standard intravenous chemotherapy improves outcomes for people with stomach or esophageal cancer that has spread to the lining of the abdomen (peritoneal metastasis).
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have stomach or lower esophageal cancer confirmed by biopsy
- Cancer has spread to the lining of your abdomen (confirmed by biopsy or fluid sample)
- You have had a laparoscopy (small camera surgery) to check the extent of spread within the last 4 weeks
- You are well enough to carry out daily activities (ECOG 0-1)
- You are at least 18 years old and expected to live at least 3 more months
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of heated chemotherapy placed directly in the abdomen (HIPEC), chemotherapy given through a vein and the abdominal cavity (NIPS), and an immunotherapy drug (tislelizumab) for people with stomach cancer that has spread to the lining of the abdomen. The goal is to see if this approach can shrink the cancer enough to allow for surgery.
This trial tests adding the chemotherapy drug paclitaxel directly into the abdomen (intraperitoneal) along with standard IV chemotherapy for people with stomach or gastroesophageal junction cancer that has spread to the lining of the abdomen. The goal is to see if this combination helps control the cancer better than standard treatment alone.
This trial studies whether adding paclitaxel chemotherapy around the time of surgery can improve outcomes for people with stomach or gastroesophageal junction adenocarcinoma that has spread to the lining of the abdomen (peritoneum). It targets cancers confirmed by testing of belly fluid or by laparoscopy/laparotomy, and may help by treating cancer cells right at the time of surgery.
This trial tests a new way to deliver chemotherapy directly into the belly for stomach cancer that has spread to the lining of the abdomen (peritoneal metastases). It also combines two standard chemotherapy drugs. The goal is to see if this approach can help people whose cancer progressed after first treatment.
This trial tests a combination of heated chemotherapy given directly into the belly (HIPEC), standard chemotherapy (SOX), and an immunotherapy drug (sintilimab) for people with advanced stomach cancer that has spread to the lining of the abdomen. The goal is to see if this triple therapy can shrink or control the cancer better than standard treatments.
This trial tests a combination chemotherapy plan—paclitaxel (albumin-bound), oxaliplatin, and S-1 given before surgery—to try to shrink stomach cancer and improve the chance of successful tumor removal. It is for people whose cancer is locally advanced or has spread, but might still be resectable (removable) in certain cases.
Hear when a new Gastric Cancer Peritoneal Metastases trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.